CA
NZ
UK
AU
IND
US
The company release points to pivotal program data as the main driver, though the price move cannot be tied to one headline. In the PiNACLE trial of ronde-cel in third-line and later large B-cell lymphoma, 44 patients were efficacy-evaluable. The overall response rate was …
The rationale is governance and strategic change. Vishal Garg says he was removed as CEO at the August 3, 2026 board meeting, and his group claims written consents from over 51% of voting shares to remove five of eight directors. The company has not …
The rationale is an earnings beat on a low expectation base plus cash generation. Free cash flow of about USD 121 million more than doubled year over year, and the full-year target is at least USD 250 million including legal payments. At the Acima …
The rationale is anEarningsand profitability inflection rather than growth. Integrated Care revenue rose 2% to USD 398.5 million at an 18.8% adjusted EBITDA margin, while BetterHelp revenue fell 13% to USD 206.6 million at a 2.2% margin. Investors tend to pay more for a …
The rationale is an earnings surprise from a low base. A company that has been shrinking sales while cutting costs and reducingDebtcan see profit expectations reset sharply when quarterly earnings are six times the consensus. Short interest and squeeze mechanics can amplify the move …
The rationale is an earnings beat with a guidance raise, backed by a buyback. Revenue beat consensus by USD 15.5 million, and fourth-quarter revenue guidance of USD 218 million at the midpoint topped the USD 212.5 million consensus by about 2.6%, while the EBITDA …
No single catalyst for the weekly move was identified beyond the filed acquisition, so the following is general context. SmallNasdaqcompanies often re-rate when a transformative deal changes the story, when a low base attracts momentum traders, or when a tiny free float meets sudden …
The rationale is anEarningsbeat and raised operating scale combined with buybacks. Since September 2025 the company has repurchased about USD 115 million of stock, cutting shares outstanding by about 11.2 million, or 16%. In the third quarter it bought about 800,000 shares for USD …
The rationale combines guidance, deleveraging and a buyback. Full year variable marketing margin guidance is USD 370 million to USD 375 million, implying 17% revenue growth and 14% adjusted EBITDA growth at the midpoints. Fourth quarter guidance is revenue of USD 315 million to …
Key HighlightsClarivate (NYSE:CLVT) trades at USD 2.21 after a 4.19% session gain, with 22.72% over 1 week and 52.34% over 1 month, ranking sixteenth on a published one-month small cap screener snapshot.Third-quarter 2026 adjusted diluted EPS was USD 0.21 against USD 0.18 a year …
Please wait processing your request...